Kantar Health, a leading global healthcare consulting firm, has partnered with Data2Life, a Tel Aviv-based technology company, to provide early signal intelligence on drug side effects based on “real-world” information to the pharmaceutical industry. Multilayered data combined with machine learning and analysis will give pharmaceutical and biotech companies timely indicators to strengthen pharmacovigilance and risk management, reveal innovation opportunities and optimize clinical trial design.
“Adverse-event reporting is a vital function for pharma and biotech companies as serious or fatal side effects can open up these companies to substantial legal and financial liability,” said Jeremy Brody, executive vice president, Kantar Health. “Data2Life collects data from multiple real-world sources, and our partnership allows us to help pharma harness the power of these data to address their safety and surveillance issues, as well as better focus development resources and foster innovations that can vastly improve patient quality of life.”
Kantar Health clients on pharmacovigilance, research and medical affairs teams can use these data and insights to:
- More efficiently and effectively meet regulatory requirements for adverse-event reporting
- Focus development resources on the highest potential opportunities
- Refine clinical trial designs for increased effectiveness, targeted populations or new indications for existing products
- Gain new competitive insights into how drugs perform relative to other products from a safety perspective
Data2Life aggregates, standardizes and validates data from regulatory agencies (including the U.S. Food and Drug Administration and Health Canada), anonymized electronic health records (EHRs) and social media. Through a partnership with Clalit Health Services, the world’s second-largest HMO, Data2Life has access to anonymized records from a centralized EHR system that includes almost two decades of data on more than 4.5 million patients. These comprehensive records include 20 years of longitudinal data to provide the full patient experience – inpatient, outpatient, pharmacy, lab and imaging.
“There is great value in having these diverse datasets available through one interface, along with analytical tools that can provide insights relative to the industry goals of drug safety and innovation,” said Itzik Lichtenfeld, Ph.D., founder and CEO, Data2Life. “Clearer visibility into drug events offers specific and compelling opportunities for pharmaceutical companies to strengthen post-approval drug safety practices, as well as to respond more quickly to an increasing number of regulatory inquiries.”
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP. For more information, please visit http://www.kantarhealth.com.
About Data2Life
Data2Life serves the life sciences and healthcare industries with real-world intelligence and easy-to-use analytical tools on drug events and trends. By combining, normalizing and cross-validating data from regulatory agencies, clinical electronic health records and social media, Data2Life provides broader and clearer visibility into drug effects experienced by patients after launch. The company has a partnership with Clalit Health Services, the world’s second largest HMO. Learn more at http://www.data2life.com.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/08/prweb12904648.htm
Kantar Health Stacy Sevcik +1 (314) 529-3062
